First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.
Sarina A Piha-PaulBinghe XuEcaterina E DumbravaSiqing FuDaniel D KarpFunda Meric-BernstamDavid S HongJordi A RodonApostolia M TsimberidouKanwal RaghavJaffer A AjaniAnthony P ConleyFrank MottYing FanJean FanPeng PengHui WangShumao NiCaixia SunXiaoyan QiangWendy J LevinBrenda NgoQinhua Cindy RuFrank WuMilind M JavlePublished in: The oncologist (2024)
Tinengotinib was well tolerated with favorable pharmacokinetic characteristics. Preliminary findings indicated potential clinical benefit in FGFR inhibitor-refractory cholangiocarcinoma, HER2-negative breast cancer (including TNBC), and CRPC. Continued evaluation of tinengotinib is warranted in phase II trials.